MGI responded today to a motion filed by Illumina in the US District Court for the Northern District of California for a preliminary injunction to try to prevent MGI from distributing sequencers in the US, saying Illumina’s motion is without merit.

Illumina's motion for a preliminary injunction is not directed to MGI's novel CoolMPS reagent kits or the use of MGI's sequencers with the CoolMPS reagent kits.  Rather, Illumina's motion is directed at preventing even minimal use of MGI’s reagent kits for comparison with MGI's CoolMPS chemistry. Thus, MGI believes that this motion is an example of Illumina attempting to tarnish MGI’s reputation, stifle competition, and limit consumer choice in the U.S. market.